A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

被引：2

作者：

Brivio, Erica ^{[1
,2
]}

Hoogendijk, Raoull ^{[1
]}

Chantrain, Christophe ^{[3
]}

Rialland, Fanny ^{[4
]}

Contet, Audrey ^{[5
]}

Elitzur, Sarah ^{[6
]}

Dalla-Pozza, Luciano ^{[7
]}

Kallay, Krisztian ^{[8
]}

Li, Chi Kong ^{[9
]}

Kato, Motohiro ^{[10
]}

Markova, Inna V. ^{[11
]}

Schmiegelow, Kjeld ^{[12
]}

Bodmer, Nicole ^{[13
]}

Pieters, Rob ^{[1
]}

Zwaan, Christian Michel ^{[1
,2
]}

机构：

[1] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[2] Erasmus MC, Dept Pediat Oncol Hematol, Sophia Childrens Hosp, Rotterdam, Netherlands

[3] CHC Liege, Clin Esperance, Div Pediat Hematol Oncol, Montegnee, Belgium

[4] CHU Nantes, Nantes, France

[5] CHRU Nancy, Childrens Hosp, Dept Hematol & Oncol, Vandoeuvre Les Nancy, France

[6] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol, Petah Tiqwa, Israel

[7] Childrens Hosp Westmead, Canc Ctr Children, Westmead, NSW, Australia

[8] Cent Hosp Southern Pest, Pediat Hematol & Stem Cell Transplantat Dept, Natl Inst Hematol & Infect Dis, Budapest, Hungary

[9] Chinese Univ Hong Kong, Dept Paediat, Prince Wales Hosp, Hong Kong, Peoples R China

[10] Natl Ctr Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan

[11] First Pavlov State Med Univ St Petersburg, Raisa Gorbacheva Mem Sci Inst Children Oncol Hema, St Petersburg, Russia

[12] Rigshosp Univ Hosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark

[13] Univ Childrens Hosp Zurich, Zurich, Switzerland

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3890

引用

页数：4

共 50 条

[31] Management of Important Adverse Events Associated with Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia [J].

Kebriaei, Partow ;

van Besien, Koen ;

Cutler, Corey ;

de Lima, Marcos ;

Giralt, Sergio ;

Lee, Stephanie ;

Marks, David ;

Merchant, Akil ;

Stock, Wendy ;

Stelljes, Matthias .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 :S261-S261

[32] Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia [J].

Darcin, Tahir ;

Yigenoglu, Tugce Nur ;

Sahin, Derya ;

Bakirtas, Mehmet ;

Basci, Semih ;

Merdin, Alparslan ;

Yildiz, Jale ;

Ulu, Bahar Uncu ;

Tetik, Aysegul ;

Iskender, Dicle ;

Cakar, Merih Kizil ;

Dal, Mehmet Sinan ;

Altuntas, Fevzi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S192-S193

[33] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN COLOMBIA [J].

Arciniegas, J. ;

Sossa, C. ;

Nakandakari, M. L. ;

Reyes Sanchez, J. M. .

VALUE IN HEALTH, 2023, 26 (06) :S88-S88

[34] Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma [J].

May Garrett ;

Ana Ruiz-Garcia ;

Kourosh Parivar ;

Brian Hee ;

Joseph Boni .

Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46 :211-222

[35] PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN [J].

Jabbour, E. ;

Advani, A. ;

Stelljes, M. ;

Stock, W. ;

Liedtke, M. ;

Goekbuget, N. ;

Martinelli, G. ;

O'Brien, S. ;

White, J. Liang ;

Wang, T. ;

Paccagnella, M. L. ;

Sleight, B. ;

Vandendries, E. ;

DeAngelo, D. J. ;

Kantarjian, H. M. .

HAEMATOLOGICA, 2017, 102 :198-198

[36] Phase I Study of Inotuzumab Ozogamicin in Children with Relapsed/Refractory CD22-Positive Acute Lymphoblastic Leukemia in Japan (Ino-Ped-All-1) [J].

Nakayama, Hideki ;

Ogawa, Chitose ;

Sekimizu, Masahiro ;

Fujisaki, Hiroyuki ;

Kosaka, Yoshiyuki ;

Hashimoto, Hiroya ;

Saito, Akiko ;

Horibe, Keizo .

PEDIATRIC BLOOD & CANCER, 2021, 68

[37] Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia [J].

Dahl, Jenny ;

Marx, Kayleigh ;

Jabbour, Elias .

EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (04) :329-334

[38] Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia [J].

Tvito, Ariella ;

Rowe, Jacob M. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (12) :1557-1564

[39] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Ueda, Tomoaki ;

Fukushima, Kentaro ;

Kusakabe, Shinsuke ;

Yoshida, Koki ;

Suga, Makiko ;

Nakai, Ritsuko ;

Koike, Midori ;

Hino, Akihisa ;

Akuta, Keigo ;

Toda, Jun ;

Nagate, Yasuhiro ;

Doi, Yukiko ;

Fujita, Jiro ;

Yokota, Takafumi ;

Hosen, Naoki .

LEUKEMIA RESEARCH REPORTS, 2022, 17

[40] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (vol 33, pg 884, 2018) [J].

Bhojwani, Deepa ;

Sposto, Richard ;

Shah, Nirali N. ;

Rodriguez, Vilmarie ;

Yuan, Constance ;

Stetler-Stevenson, Maryalice ;

O'Brien, Maureen M. ;

McNeer, Jennifer L. ;

Quereshi, Amrana ;

Cabannes, Aurelie ;

Schlegel, Paul ;

Rossig, Claudia ;

Dalla-Pozza, Luciano ;

August, Keith ;

Alexander, Sarah ;

Bourquin, Jean-Pierre ;

Zwaan, Michel ;

Raetz, Elizabeth A. ;

Loh, Mignon L. ;

Rheingold, Susan R. .

LEUKEMIA, 2019, 33 (04) :1061-1062

← 1 2 3 4 5 →